This issue of Hematology/Oncology Clinics, guest edited by Drs. Ronald Hoffman, Ross Levine, John Mascarenhas, and Raajit Rampal, is dedicated to Myeloproliferative Neoplasms. This issue is one of six selected each year by the series consulting editors, Drs. George P. Canellos and Edward J. Benz. Topics in this issue include—but are not limited to— Overview of pathophysiology and potential drug targets, The role of the megakaryocyte, Epigenetics, Genetics, Novel technologies for understanding MPN biology, Important pathology considerations, Current Clinical investigations, Quality of life, Application of stem cell therapy, Immunotherapy approaches, Clinical unmet needs in ET/PV, Accelerated and blast phase MPNs, Epidemiology, Thrombotic and hemorrhagic complications, Murine modeling, The microenvironment in MPNs, MDS/MPN overlap syndrome, and Advancing effective clinical trial designs.

This issue of Hematology/Oncology Clinics, guest edited by Drs. Ronald Hoffman, Ross Levine, John Mascarenhas, and Raajit Rampal, is dedicated to Myeloproliferative Neoplasms. This issue is one of six selected each year by the series consulting editors, Drs. George P. Canellos and Edward J. Benz. Topics in this issue include—but are not limited to— Overview of pathophysiology and potential drug targets, The role of the megakaryocyte, Epigenetics, Genetics, Novel technologies for understanding MPN biology, Important pathology considerations, Current Clinical investigations, Quality of life, Application of stem cell therapy, Immunotherapy approaches, Clinical unmet needs in ET/PV, Accelerated and blast phase MPNs, Epidemiology, Thrombotic and hemorrhagic complications, Murine modeling, The microenvironment in MPNs, MDS/MPN overlap syndrome, and Advancing effective clinical trial designs.

This issue of Hematology/Oncology Clinics, guest edited by Drs. Ronald Hoffman, Ross Levine, John Mascarenhas, and Raajit Rampal, is dedicated to Myeloproliferative Neoplasms. This issue is one of six selected each year by the series consulting editors, Drs. George P. Canellos and Edward J. Benz. Topics in this issue include—but are not limited to— Overview of pathophysiology and potential drug targets, The role of the megakaryocyte, Epigenetics, Genetics, Novel technologies for understanding MPN biology, Important pathology considerations, Current Clinical investigations, Quality of life, Application of stem cell therapy, Immunotherapy approaches, Clinical unmet needs in ET/PV, Accelerated and blast phase MPNs, Epidemiology, Thrombotic and hemorrhagic complications, Murine modeling, The microenvironment in MPNs, MDS/MPN overlap syndrome, and Advancing effective clinical trial designs.